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Abstract 
Rationale & Objective 
People with idiopathic pulmonary fibrosis (IPF) have been shown to be at an increased risk 
of cardiovascular disease but reasons for this are unknown. The aim of this study was to 
compare the prevalence of common cardiovascular risk factors in people with IPF and the 
general population and establish the incidence of ischaemic heart disease (IHD) and stroke 
after the diagnosis of IPF, controlling for these risk factors.  
Methods 
We used data from a large United Kingdom primary care database to identify incident cases 
of IPF and matched general population controls. We compared the prevalence of risk factors 
for cardiovascular disease and prescription of cardiovascular medications in people with IPF 
(before diagnosis) with general population controls, and assessed the incidence of IHD and 
stroke in people with IPF (after diagnosis) compared to controls. 
Results 
We identified 3,211 cases of IPF and 12,307 controls. Cases with IPF were more likely to 
have a record of hypertension (odds ratio [OR] 1.31, 95% confidence interval [CI] 1.19 - 
1.44), and diabetes (OR 1.20, 95% CI 1.07 - 1.34) compared with controls; they were also 
more likely to have been prescribed several cardiovascular drugs. The rate of first time IHD 
events was more than twice as high in cases compared to controls (rate ratio [RR] 2.32, 95% 
CI 1.85-2.93; p<0.001) but the incidence of stroke was only marginally higher (p=0.09). Rate 
ratios for IHD and stroke were not altered substantially after adjusting for cardiovascular 
risk factors. 
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Conclusion 
Several cardiovascular risk factors were more prevalent in people with IPF; however this did 
not account for the increased rate of IHD in this group of patients.  
Abstract word count 257 
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Introduction 
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with few treatment 
options. The most common cause of morbidity and mortality in people with this condition is 
progression of fibrosis leading to respiratory failure, but several studies have identified an 
increased risk of acquiring comorbidities which contribute to the disease burden.1,2  
Cardiovascular diseases such as ischaemic heart disease and cerebrovascular disease 
constitute an important group of co-morbid conditions affecting those with IPF.1-4  In a 
cohort of people referred for lung transplantation, Nathan and colleagues found significant 
coronary artery disease to be increased in people with IPF compared with people with 
chronic obstructive pulmonary disease (COPD), with worse outcomes for those with both 
IPF and coronary artery disease.5 Using United Kingdom (UK) longitudinal electronic health 
records, we have previously demonstrated that people with IPF have an increased risk of 
cardiovascular disease even before the IPF diagnosis is made.3 
The reason behind this increase in cardiovascular disease seen in IPF is unknown. It has been 
suggested that certain risk factors for cardiovascular disease such as diabetes mellitus are 
more prevalent in those with IPF.6-8A study by Reed and colleagues found a greater 
prevalence of hyperlipidaemia, hypertension and higher body mass index (BMI) amongst 
people with IPF compared to people with COPD.8 Studies looking at the rates of cigarette 
smoking amongst those with IPF are discordant; some showing a small increase in rates of 
smoking9 and others finding no difference from the general population. 10 The prevalence of 
cardiovascular risk factors in people with IPF has yet to be explored in a large 
epidemiological study. 
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The aim of this study was to compare the prevalence of cardiovascular risk factors, and 
prescriptions for drugs commonly used to manage cardiovascular disease, in people with IPF 
to the general population. We also aimed to establish the incidence of ischaemic heart 
disease and stroke after the diagnosis of IPF controlling for the presence of cardiovascular 
risk factors and prescriptions for cardiovascular drugs. 
Methods 
Data source 
We used The Health Improvement Network (THIN), a UK longitudinal database of electronic 
primary care records containing information recorded in routine clinical care, from face to 
face consultations, and following communication from secondary care. 11 Anonymised 
patient-level data include demographic information, medical diagnoses (coded using Read 
codes) and prescriptions. The version of THIN used for this study included information from 
511 practices entered up to September 2011. 
Study population 
We identified individuals with a new diagnosis of IPF made after January 1st 2000 (see 
Appendix 1). Cases were included if their first diagnosis of IPF was recorded at least 12 
months after registration with the practice, and if they were at least 40 years when first 
diagnosed. This definition was used to capture incident cases of IPF and improve diagnostic 
specificity.     
We excluded people with co-existing diagnoses of connective tissue disease (Appendix 2), or 
a record of extrinsic allergic alveolitis, sarcoidosis, pneumoconiosis or asbestosis (Appendix 
3) in addition to IPF because it was not clear which diagnosis was correct.  
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For each incident case of IPF, we randomly selected up to four general population controls, 
matched on age, gender and general practice. Each case was assigned an index date which 
corresponded to their first diagnosis of IPF; matched controls were assigned the same date 
as their case. All cases and controls had at least 12 months of computerised records prior to 
their index date. 
Exposures and outcomes 
We extracted data on diagnoses of ischaemic heart disease (IHD), ischaemic and 
haemorrhagic stroke, hypertension, diabetes, hypercholesterolaemia and prescriptions for 
cardiovascular and diabetic medications, as well as smoking habit (current smoker, ex-
smoker, never smoker) using the data recorded closest to the index date, and BMI. 
Statistical Analysis 
We conducted a case-control study to compare the prevalence of risk factors for 
cardiovascular disease and prescription of cardiovascular medications in people with IPF, 
with general population controls. Conditional logistic regression was used to compare the 
odds of these exposures, prior to the index date, in cases and controls. We looked for 
evidence of effect modification by age and sex. 
We performed a cohort study to investigate whether incidence of IHD or stroke was 
increased after diagnosis of IPF. For these analyses, we excluded people who had diagnoses 
of IHD or stroke prior to the index date. All individuals were assigned a start date which was 
their index date, and a stop date which was the first of: date of the outcome, date of death, 
or last date of data collection. Crude incidence rates of IHD and stroke were calculated. Cox 
regression, stratifying for the matching factors, was used to estimate rate ratios for first 
time IHD and stroke events in cases, compared to controls. We looked for evidence of 
 6  
confounding by cardiovascular risk factors and prescriptions. Multiplicative interaction 
terms were applied to test for interactions between IPF and age, sex or diabetes. 
Proportional hazards assumption was confirmed using graphical methods and scaled 
Schoenfeld residuals.  
Likelihood ratio tests were used for all hypothesis testing. Statistical analyses were 
conducted using Stata version 12 (Texas). With 3211 incident cases of IPF and 12,307 
matched controls, we had in excess of 90% power to detect an odds ratios (OR) of 1.5 or 
greater for exposures affecting 5% of controls or to detect an OR of 1.3 or greater for 
exposures affecting 10% of controls.  
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Results 
There were 3211 incident cases of idiopathic pulmonary fibrosis (IPF) and 12,307 matched 
general population controls. The cases consisted mainly of men (63.9%) and mean age at 
diagnosis was 75.7 years (standard deviation [SD]: 9.8). Both cases and controls had a 
median duration of 9.8 years (interquartile range [IQR]: 5.6-13.7) of computerised records 
prior to the index date.  
Case-control study 
Cases with IPF were 31% more likely to have a record of hypertension (odds ratio [OR] 1.31, 
95% confidence interval [CI] 1.19 to 1.44; p<0.001), and  20% more likely to have a record of 
diabetes mellitus prior to receiving a diagnosis of IPF compared to general population 
controls (OR 1.20, 95% CI 1.07 to 1.34; p<0.001). We also found that cases were more than 
twice as likely to be ex-smokers before the diagnosis of IPF was made compared to controls 
(see Table 1).  Cases with IPF were more likely to have been prescribed anti-anginals, ACE 
inhibitors or angiotensin II receptor antagonists, digoxin, anti-platelets and lipid lowering 
medication compared to general population controls (see Table 2). There was no evidence 
of effect modification by age or sex on any of these risk factors. 
Cohort study 
Median follow up time after the index date was 1.7 years (IQR 0.6 to 3.6) in cases with IPF 
and 3.3 years (1.5 to 5.8) for controls. During this time, 135 cases and 474 controls had a 
first time ischaemic heart disease event. The rate of first time ischaemic heart disease 
events was more than two times higher in cases with IPF compared to general population 
controls (rate ratio [RR] 2.32, 95% CI 1.85-2.93; p<0.001)(See Table 3, Figure 1). The 
incidence rate of stroke during the follow up period was 11.3 per 1000 person years (95% CI 
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9.2 to 14.0) in cases with IPF and 10.3 per 1000 person years (95% CI 9.5 to 11.3) in the 
controls (see Table 3).  
The rate ratios for ischaemic heart disease and stroke were not altered substantially after 
adjusting for the risk factors for cardiovascular disease listed in Table 1 or prescription of 
cardiovascular drugs listed in Table 2. There was no evidence of a statistical interaction 
between IPF and age or sex in any of our findings. Despite there being weak evidence that 
the effect of IPF on first time ischaemic heart disease events was modified by diabetes 
(p=0.21), the stratum specific ischaemic heart disease rate ratio for IPF with and without 
diabetes were 3.34 (95% CI 1.79 to 6.22) and 2.13 (95% CI: 1.64 to 2.77) respectively.  
Thirteen per cent of the study population (2,053 individuals) was lost to follow up; this was 
similar in cases and controls (12.9% vs. 13.3%; p=0.57, chi squared test). A higher proportion 
of individuals who were lost to follow up did not have any cardiovascular risk factors and 
were not prescribed anti-anginals, anti-platelets or lipid lowering drugs. There was no 
evidence that the proportional hazards assumptions in our final models for ischaemic heart 
disease (p= 0.31) or stroke (p=0.49) were not met. 
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Table 1: Odds ratios for risk factors of cardiovascular disease comparing incident cases of 
idiopathic pulmonary fibrosis and matched general population controls 
Risk factor   Cases 
(n=3211) (%) 
Controls 
(n=12,307) 
(%) 
Odds Ratio 
(95% CI) 
p 
value* 
Hypertension No 2389 (74.4) 9670 (78.7) 1.00  
 Yes 822 (25.6) 2628 (21.3) 1.31 (1.19-1.44) <0.001 
Diabetes No 2761 (86.0) 10,826 (88.0) 1.00  
 Yes 450 (14.0) 1481 (12.0) 1.20 (1.07-1.34) 0.003 
Hyperlipidaemia No 1361 (42.4) 5151 (41.9) 1.00  
 Yes 1850 (57.6) 7156 (58.2) 0.98 (0.90-1.06) 0.63 
      
      
Smoking habit Never 
smoked 
972 (30.3) 5125 (41.7) 1.00  
 Ex-smoker 1243 (38.7) 3233 (26.3) 2.20 (1.99-2.43)  
 Current 
smoker 
434 (13.54) 1661 (13.45) 1.44 (1.27-1.65) <0.001 
 Missing 
information 
562 (17.5) 2255 (18.6) -  
Body Mass Index 
(kg/m2) 
<18.5 88 (2.7) 197 (1.6) 1.77 (1.35-2.32)  
 18.5-24.9 946 (29.5) 3662 (29.8) 1.00  
 25-30 1309 (40.8) 4794 (39.0) 1.06 (0.96-1.17)  
 >31 485 (15.1) 1636 (13.3) 1.16 (1.02-1.32) <0.001 
 Missing 
data 
383 (12.0) 2018 (16.4) -  
*p value from Likelihood ratio test 
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Table 2: Odds ratios for prescribed cardiovascular medication comparing incident cases of 
idiopathic pulmonary fibrosis and matched general population controls 
Cardiovascular 
drug 
 Cases (n=3211) 
(%) 
Controls 
(n=12,307) 
(%) 
Odds Ratio (95% 
CI) 
p 
value* 
Beta blockers No 2021 (62.9) 8102 (65.8) 1.00  
 Yes 1190 (37.1) 4205 (34.2) 1.15 (1.05-1.24) 0.001 
ACE inhibitors or 
angiotensin II 
receptor 
antagonists 
No 1755 (54.7) 8043 (65.4) 1.00  
 Yes 1456 (45.3) 4264 (34.7) 1.64 (1.51-1.78) <0.001 
Calcium channel 
blockers 
No 2083 (64.9) 8399 (68.3) 1.00  
 Yes 1128 (35.1) 3908 (31.7) 1.18 (1.08-1.28) <0.001 
Digoxin No 2933 (91.3) 11,567 (94.0) 1.00  
 Yes 278 (8.7) 740 (6.0) 1.49 (1.28-1.72) <0.001 
Nitrates No 2221 (69.2) 10,006 (81.3) 1.00  
 Yes 990 (30.8) 2301 (18.7) 2.00 (1.83-2.20) <0.001 
Anti-platelets No 1591 (49.6) 7442 (60.5) 1.00  
 Yes 1620 (50.5) 4865 (39.5) 1.65 (1.52-1.80) <0.001 
Warfarin No 2820 (87.8) 11,265 (91.5) 1.00  
 Yes 391 (12.2) 1042 (8.5) 1.52 (1.34-1.73) <0.001 
Lipid lowering 
drugs 
No 1940 (60.4) 8147 (66.2) 1.00  
 Yes 1271 (39.6) 4160 (33.8) 1.36 (1.25-1.49) <0.001 
*p value from Likelihood Ratio Test
 11  
Table 3: Incidence rates and rate ratios for ischaemic heart disease and stroke, comparing 
incident cases of idiopathic pulmonary fibrosis and matched general population controls. 
Outcome Number 
of 
events 
in cases 
Person-
years 
Crude 
rate in 
cases 
(per 
1000 
pyrs)  
(95% 
CI) 
Number 
of 
events 
in 
controls 
Person-
years 
Crude 
rate in 
controls 
(per 
1000 
pyrs)  
(95% CI) 
Rate 
ratio* 
(95% 
CI) 
p 
value# 
Ischaemic 
heart 
disease 
135 7618.7 17.6 
(14.8-
20.8) 
474 47786.9 9.9 (9.2-
10.9) 
2.32 
(1.85-
2.93) 
<0.001 
Stroke 87 7671.6 11.3 
(9.2-
14.0) 
523 50508 10.3 
(9.5-
11.3) 
1.25 
(0.97-
1.61) 
0.09 
*Rate ratios stratified for matching variables                                                         #p value from Likelihood Ratio Test 
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Figure 1: Cumulative incidence of ischaemic heart disease in incident cases of IPF and 
general population controls 
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Discussion 
In this large population based study, we found that people with idiopathic pulmonary 
fibrosis (IPF) were more likely to have a recorded diagnosis of hypertension and diabetes 
mellitus before the diagnosis of IPF was made compared to the general population. People 
with IPF were also more likely to be prescribed anti-anginals, anti-platelets and lipid 
lowering medication compared to general population controls. Individuals with IPF had 
twice the rate of first time ischaemic heart disease events after their diagnosis compared to 
the general population, after adjusting for cardiovascular risk factors and prescription of 
cardiovascular drugs. In addition to the above, there was weak evidence that the incidence 
rate of strokes was higher in people with IPF. 
The main strength of this study is the large number of individuals included in the study 
population and the long period of time over which the data were collected. This has enabled 
us to investigate in detail individual risk factors for cardiovascular disease and prescription 
of commonly used cardiovascular drugs, and to explore the possibility of confounding and 
effect modification. Studies of this nature and magnitude are difficult to conduct in a clinical 
setting. Our cohort study was restricted to individuals who had never had a previous 
ischaemic heart disease event or stroke, as the risk of subsequent cardiovascular events are 
likely to be different from the first. As our study is population based, the incident cases 
included are likely to capture individuals across the disease spectrum and avoid selection 
bias that can occur in studies conducted in tertiary referral centres. Furthermore, the use of 
electronic medical records limits the possibility of recall or observer bias. 
The main limitation of our study is the validity of diagnoses of IPF within the dataset. We 
have previously demonstrated that diagnoses of pulmonary fibrosis in electronic primary 
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care are records are accurate.10 Furthermore, as IPF is usually diagnosed in secondary care, 
it seems unlikely that a record of this diagnosis will be found in primary care records without 
confirmation from secondary care. The age distribution of cases with IPF in this study is 
similar to other population based cohorts of IPF,12-16 providing reassurance of the validity of 
diagnosis of IPF in these data. In addition, a study by Fell and colleagues demonstrated that 
age is a strong predictor of IPF in patients with an atypical Usual Interstitial Pneumonia (UIP) 
radiographic pattern, whereby individuals over 65 years had 89% specificity for confirming 
IPF on lung biopsy.17 Eighty-one per cent of cases were over the age of 65 in our dataset, 
providing further evidence that most of our cases have UIP. In addition to this, the mortality 
rate for cases with IPF during the study period was 193.7 per 1000 person years (95%  CI: 
184.2 to 203.8) and the median survival was 3.5 years, both of which are similar to other 
population studies of IPF. 12,16,18-20 There is also the possibility of misclassification of 
ischaemic heart disease, stroke and/or cardiovascular risk factors, however studies have 
also demonstrated the validity of recording of medical diagnoses21,22 and prescription 
records23 in computerised longitudinal general practice databases.  
The possibility of ascertainment bias in our cohort study needs to be acknowledged. 
Individuals with chronic diseases such as IPF are more likely than the general population to 
see their GP regularly, and this may explain why other illnesses are more likely to be 
investigated and diagnosed. This may have led to an overestimation in the association 
between IPF and the cardiovascular outcomes. However, our findings  show a weak 
association between IPF and stroke, suggesting that any ascertainment bias, if present, is 
likely to be minimal.  Another potential limitation of the study is that the general practices 
are self-selecting with regards to contributing to THIN. However, the population of 
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individuals from general practices that do contribute to THIN are thought to be broadly 
representative of the UK population. Thirteen per cent of the study population were lost to 
follow up, a higher proportion of which were people without cardiovascular risk factors or 
prescriptions for cardiovascular medication. This raises the possibility that people who were 
lost to follow up may have had a lower rate of ischaemic heart disease or stroke than those 
who remained in the study. Another limitation that needs consideration is that the median 
duration of follow-up after the index date for cases with IPF was shorter compared to the 
controls (1.7 vs. 3.3 years), which may have resulted in an underestimation in the incidence 
of IHD amongst cases. 
The findings from our study are consistent with previous studies that have demonstrated an 
association between IPF and cardiovascular disease.1,3-5,24,25 A study by Panos et. al. showed  
that ischaemic heart disease and heart failure were common causes of death amongst 
patients with IPF. 26 In a cross sectional study of 630 patients referred for lung 
transplantation evaluation, Kizer et. al. found increased prevalence of angiographic coronary 
artery disease in patients with fibrotic lung disease compared to those with non-fibrotic lung 
diseases, after controlling for traditional risk factors (OR 2.18, 95%CI: 1.46-11.9).24  This is 
similar to the findings of another study in lung transplantation candidates that found that 
angiographic evidence of coronary artery disease was significantly more common in people 
with lung fibrosis compared to those with chronic obstructive pulmonary disease (COPD) 
despite the smoking prevalence in being much higher in people with COPD.25 A recent study 
of 73 IPF and 56 COPD patients found the prevalence of coronary artery disease was higher 
in those with IPF (65.8% vs. 46.1%), with more severe disease also being more common in 
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those with IPF.5 People with IPF who have severe coronary artery disease also appear to 
have worse outcomes. 5 
Using UK primary care data, we have previously found that people with IPF had an increased 
risk of acute coronary syndrome, angina and prescription of cardiovascular drugs compared 
to the general population, even before the diagnosis of IPF was made.3 We also found that 
the risk of acute coronary syndrome increased to three-fold in people with IPF compared to 
the general population after the diagnosis of IPF was established (RR 3.14, 95%CI: 2.02-
4.87).3  Similar findings were reported from a hospital based case-control study which 
showed that  the prevalence of coronary artery disease was five times higher in patients 
with IPF (OR 5.37, 95% CI 1.52-19.00; p<0.01).4  
Despite the possibility of ascertainment bias, our findings suggest that IPF is an independent 
risk factor for ischaemic heart disease. This is consistent with the findings of other studies 
and suggests that simply targeting risk factors for cardiovascular disease in people with IPF 
may not be sufficient to reduce the incidence of ischaemic heart disease. It is possible, 
however, that IPF and ischaemic heart disease share other aetiological risk factors. Studies 
have suggested that people with IPF have an increased tendency to clot,14,27,28 and have 
higher Factor VIII levels than the general population.14  Previous studies have also 
demonstrated that elevated Factor VIII levels are associated with an increased risk of 
coronary artery disease. 29,30 
In conclusion, we have found that people with IPF have increased prevalence of 
cardiovascular risk factors. People with IPF also have an increased risk of ischaemic heart 
disease that cannot be attributed to the increased prevalence of these risk factors alone. 
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While treatment of these risk factors must be considered during routine care of people with 
IPF, further research into the biological mechanism behind the increased risk is warranted. 
 18  
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